The U.S. Food and Drug Administration (FDA) recently approved Epizyme, Inc’s tazemetostat (TAZVERIK) for the treatment of adult and pediatric patients with metastatic or advanced epithelioid sarcoma (AES).
AES is a rare sarcoma that affects the soft tissue in upper extremities. The approval of tazemetostat continues to highlight the FDA’s efforts in helping increase the quality of lives of patients who suffer from rare disorders.
Please read more about the approval here. And more about AES here.
The views and opinions expressed here are those of the author and do not necessarily reflect the opinions or recommendations of the American Nurses Association, the Editorial Advisory Board members, or the Publisher, Editors and staff of American Nurse Journal. This has not been peer reviewed.